Zoetis Inc. (ZTS)

About Zoetis Inc.

Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 30% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 70% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.

As of November 3, 2026, Zoetis Inc. (ZTS) stock rose to $83.66, up 0.58% (+$0.48) versus the previous close. On the day, shares have traded between $81.53 and $83.66. That puts ZTS in the lower third of its 52-week range of $68.77 to $132.49. Zoetis Inc. operates in the pharmaceutical preparations space and carries a market capitalization of roughly $32.94 billion, with about 843.9K shares changing hands.

Latest ZTS news

• Zoetis Gears Up to Report Q3 Earnings: Here's What to ExpectYahoo Finance· Nov 3, 9:15 AM ET
• Insights Into Zoetis (ZTS) Q3: Wall Street Projections for Key MetricsYahoo Finance· Nov 3, 8:15 AM ET
• Amneal Pharmaceuticals (AMRX) Q3 Earnings and Revenues Top EstimatesYahoo Finance· Nov 3, 6:25 AM ETAMRX
• 1 healthcare stock with impressive fundamentals and 2 we ignoreYahoo Finance· Nov 3, 6:09 AM ET
• IDEXX Soars 20% on Beat-and-Raise Quarter: “Early Innings of a Broad-Based Innovation Cycle”tikr.com· Nov 2, 1:32 PM ET
• 4D Molecular Therapeutics, Inc. (FDMT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Yahoo Finance· Nov 2, 9:00 AM ETFDMT
• IDEXX Laboratories Reports Soon: How Has The Stock Reacted To Past Earnings?trefis.com· Oct 30, 5:57 AM ETIDXX
• Zoetis (ZTS) Ascends While Market Falls: Some Facts to NoteYahoo Finance· Oct 29, 5:15 PM ET

Source: Yahoo Finance RSS · Updated November 3, 2026

Want ZTS headlines, alerts and AI research in one place? Create a free account →

• $ZTS reports Thursday before the open, and the category table in its last 10-Q shows a pretty lopsided mix heading in. Dermatology revenue fell to 398 million dollars in Q2 from 473 million a year earlier, and pain and sedation slipped to 217 million from 223 million, while pa…

  @KryptonResearch14· Nov 3, 12:04 AM ET

• $ZTS Really good write-up that perfectly summarizes ZTS's present situation. So if you want to bring your ZTS knowledge up to date or just discover ZTS, this is required reading. https://everyticker.com/quote/ZTS/analysis/zoetis-companion-animal-margin-compression-tests-a-…

  @NVDAMillionaire· Nov 2, 3:43 AM ET

• $ZTS not that the market cares about my dog lmao but cytopoint is so much better than apoquel. Take doggo for the shot and you don’t have to give a pill every day

  @inthegrove· Oct 30, 2:38 PM ET· Bullish

• $ZTS Compared to anything AI related the stock is cheap. I dont think its a home run from here with this debt, but a single

  @OffHisGame88· Oct 30, 11:06 AM ET

• $ZTS closed for 10% reenter sub 70

  @Doornumber3· Oct 28, 3:48 PM ET

Source: Stocktwits. User posts are opinions, not verified facts. See what's trending →